 | |
| Clinical data | |
|---|---|
| Pronunciation | /aɪˌbrɛksəˈfʌndʒɜːrp/ eye-BREKS-ə-FUN-jurp |
| Trade names | Brexafemme |
| Other names | SCY-078 |
| License data | |
| Pregnancy category |
|
| Routes of administration | oral,intravenous |
| Drug class | Antifungal |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | >99%[1] |
| Metabolism | Hydroxylation (CYP3A4) thenconjugation (glucuronidation,sulfation)[1] |
| Eliminationhalf-life | 20 hours[1] |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| UNII |
|
| KEGG | |
| ChEMBL |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C44H67N5O4 |
| Molar mass | 730.051 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ibrexafungerp, sold under the brand nameBrexafemme, is anantifungal medication used to treatvulvovaginal candidiasis (VVC) (vaginal yeast infection).[1] It is takenorally (by mouth).[1] It is also currently undergoing clinical trials for other indications via anintravenous (IV) formulation. An estimated 75% of women will have at least one episode of VVC and 40 to 45% will have two or more episodes in their lifetime.[2]
Ibrexafungerp acts viainhibition ofglucan synthase, which prevents formation of the fungalcell wall.[1]
Ibrexafungerp was approved for medical use in the United States in June 2021.[1][3] It is the first non-azole oral antifungal drug to be approved by the U.S.Food and Drug Administration (FDA) for the treatment of vaginal yeast infections.[3] The FDA considers it to be afirst-in-class medication.[4]
Ibrexafungerp isindicated for the treatment of adult andpostmenarchal pediatric females withvulvovaginal candidiasis (VVC).[1][3]
Ibrexafungerp is currently undergoing late-stage clinical trials for anintravenous formulation for the treatment of various fungal diseases, including life-threatening fungal infections caused primarily byCandida (including C. auris) andAspergillus species. It has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, againstmultidrug-resistant pathogens, includingazole- andechinocandin-resistant strains.[5]
Ibrexafungerp is a triterpenoid antifungal agent.[1] It acts viainhibition of theenzymeglucan synthase, which is involved in the formation of1,3-β-D-glucan—an essential component of the fungalcell wall.[1] The compound has concentration-dependentfungicidal activity againstCandida species.[1]
Ibrexafungerp has atime to maximal concentrations of 4 to 6 hours.[1] It ismetabolized byhydroxylation viaCYP3A4 and subsequently byglucuronidation andsulfation.[1] The medication has anelimination half-life of approximately 20 hours.[1]
This article incorporates text from this source, which is in thepublic domain.
